ArticleViruses2025
High-Throughput Discovery of Inhibitors Targeting Monkeypox Virus H1 Phosphatase.
Chengcheng Tao, Mailikezhati Alifu, Haojun Huang, Zhi Luo, Yaxian Li, Xuecen Guan, Mengmeng Liu, Junchi Hu, Wen Cui, Wei Wang
Abstract read
In one paragraphArticle in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Chengcheng TaoCollege of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Haojun HuangCollege of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Zhi LuoCenter for Novel Target and Therapeutic Intervention, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Yaxian LiCenter for Novel Target and Therapeutic Intervention, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Xuecen GuanCollege of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Mengmeng LiuCollege of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Junchi HuCenter for Novel Target and Therapeutic Intervention, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China.ORCID 0000-0001-7733-6547 Wen CuiCollege of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Wei WangCollege of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Funding
CQMU Program for Youth Innovation in Future Medicine W0073CQMU Program for Youth Innovation in Future Medicine W0094National Natural Science Foundation of China 81902063National Natural Science Foundation of China 82202505Natural Science Program of Chongqing Science and Technology Commission CSTB2022NSCQ-BHX0679Natural Science Program of Chongqing Science and Technology Commission CSTB2023NSCQ-BHX0154Natural Science Program of Chongqing Science and Technology Commission CSTB2024NSCQ-MSX0391Science and Technology Research Program of Chongqing Municipal Education Commission KJQN202300401Science and Technology Research Program of Chongqing Municipal Education Commission KJQN202300442Science and Technology Research Program of Chongqing Municipal Education Commission KJQN202400433Science and Technology Research Program of Chongqing Municipal Education Commission KJQN202500443Undergraduate Research Skills Development Program of College of Pharmacy Chongqing Medical Uni- 400 versity YCZX20250712
6 · The paper itselfAbstract
Mpox, caused by monkeypox virus (MPXV), remains a Public Health Emergency of International Concern (PHEIC) and poses a serious global health threat. Current therapeutic options for MPXV infection are limited. The orthopoxvirus dual-specificity phosphatase H1 plays critical roles in suppressing interferon signaling, regulating early viral transcription, and modulating viral core protease activity. Suppressing H1 expression markedly reduces the production of infectious viral particles, highlighting it as a promising antiviral target. Here, we developed a high-throughput enzymatic assay using p-nitrophenyl phosphate as a substrate to discover MPXV H1 inhibitors. We demonstrated that both the N-terminal helix α1, which mediates H1 dimerization, and the catalytic residue Cys110 are indispensable for enzymatic activity, validating them as potential "hot spots" for drug design. Screening identified 17 potent inhibitors with nanomolar IC
Indexed as
Antiviral AgentsEnzyme InhibitorsMonkeypox virusPhosphoric Monoester HydrolasesViral ProteinsAnimalsCatalytic DomainDrug DiscoveryHigh-Throughput Screening AssaysHumansMolecular Docking SimulationAntiviral AgentsEnzyme InhibitorsPhosphoric Monoester HydrolasesViral Proteinsenzymatic assayhigh-throughput screeninginhibitormolecular docking analysismonkeypox virusphosphatase H1
Identifiers
PMID41305514
PMCPMC12656849
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390